250 related articles for article (PubMed ID: 22104553)
1. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism.
Orbe J; Barrenetxe J; Rodriguez JA; Vivien D; Orset C; Parks WC; Birkland TP; Serrano R; Purroy A; Martinez de Lizarrondo S; Angles-Cano E; Páramo JA
Circulation; 2011 Dec; 124(25):2909-19. PubMed ID: 22104553
[TBL] [Abstract][Full Text] [Related]
2. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.
Denorme F; Wyseure T; Peeters M; Vandeputte N; Gils A; Deckmyn H; Vanhoorelbeke K; Declerck PJ; De Meyer SF
Stroke; 2016 Sep; 47(9):2419-22. PubMed ID: 27470988
[TBL] [Abstract][Full Text] [Related]
4. MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes.
Navarro-Oviedo M; Roncal C; Salicio A; Belzunce M; Rabal O; Toledo E; Zandio B; Rodríguez JA; Páramo JA; Muñoz R; Orbe J
Transl Stroke Res; 2019 Aug; 10(4):389-401. PubMed ID: 30051168
[TBL] [Abstract][Full Text] [Related]
5. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
Roncal C; Martinez de Lizarrondo S; Salicio A; Chevilley A; Rodriguez JA; Rosell A; Couraud PO; Weksler B; Montaner J; Vivien D; Páramo JA; Orbe J
Cardiovasc Res; 2017 Aug; 113(10):1219-1229. PubMed ID: 28379489
[TBL] [Abstract][Full Text] [Related]
6. Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Berny-Lang MA; Hurst S; Tucker EI; Pelc LA; Wang RK; Hurn PD; Di Cera E; McCarty OJ; Gruber A
Stroke; 2011 Jun; 42(6):1736-41. PubMed ID: 21512172
[TBL] [Abstract][Full Text] [Related]
7. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Wang L; Fan W; Cai P; Fan M; Zhu X; Dai Y; Sun C; Cheng Y; Zheng P; Zhao BQ
Ann Neurol; 2013 Feb; 73(2):189-98. PubMed ID: 23280993
[TBL] [Abstract][Full Text] [Related]
8. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential.
Machado LS; Sazonova IY; Kozak A; Wiley DC; El-Remessy AB; Ergul A; Hess DC; Waller JL; Fagan SC
Stroke; 2009 Sep; 40(9):3028-33. PubMed ID: 19628804
[TBL] [Abstract][Full Text] [Related]
9. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Liu W; Hendren J; Qin XJ; Liu KJ
Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
[TBL] [Abstract][Full Text] [Related]
10. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
[TBL] [Abstract][Full Text] [Related]
11. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tsuji K; Aoki T; Tejima E; Arai K; Lee SR; Atochin DN; Huang PL; Wang X; Montaner J; Lo EH
Stroke; 2005 Sep; 36(9):1954-9. PubMed ID: 16051896
[TBL] [Abstract][Full Text] [Related]
12. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
Copin JC; Bengualid DJ; Da Silva RF; Kargiotis O; Schaller K; Gasche Y
Eur J Neurosci; 2011 Oct; 34(7):1085-92. PubMed ID: 21895804
[TBL] [Abstract][Full Text] [Related]
13. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.
Semeraro F; Ammollo CT; Semeraro N; Colucci M
Haematologica; 2009 Jun; 94(6):819-26. PubMed ID: 19377079
[TBL] [Abstract][Full Text] [Related]
14. YangXueQingNaoWan attenuated blood brain barrier disruption after thrombolysis with tissue plasminogen activator in ischemia stroke.
Yao SQ; Ye Y; Li Q; Wang XY; Yan L; Huo XM; Pan CS; Fu Y; Liu J; Han JY
J Ethnopharmacol; 2024 Jan; 318(Pt B):117024. PubMed ID: 37572928
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CD147 (Cluster of Differentiation 147) Ameliorates Acute Ischemic Stroke in Mice by Reducing Thromboinflammation.
Jin R; Xiao AY; Chen R; Granger DN; Li G
Stroke; 2017 Dec; 48(12):3356-3365. PubMed ID: 29114092
[TBL] [Abstract][Full Text] [Related]
16. Role of tissue-type plasminogen activator in ischemic stroke.
Suzuki Y
J Pharmacol Sci; 2010; 113(3):203-7. PubMed ID: 20595786
[TBL] [Abstract][Full Text] [Related]
17. Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator.
Suzuki Y; Nagai N; Umemura K
J Pharmacol Sci; 2011; 116(1):25-9. PubMed ID: 21498957
[TBL] [Abstract][Full Text] [Related]
18. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background.
Tabrizi P; Wang L; Seeds N; McComb JG; Yamada S; Griffin JH; Carmeliet P; Weiss MH; Zlokovic BV
Arterioscler Thromb Vasc Biol; 1999 Nov; 19(11):2801-6. PubMed ID: 10559029
[TBL] [Abstract][Full Text] [Related]
19. A new rat model of thrombotic focal cerebral ischemia.
Zhang Z; Zhang RL; Jiang Q; Raman SB; Cantwell L; Chopp M
J Cereb Blood Flow Metab; 1997 Feb; 17(2):123-35. PubMed ID: 9040491
[TBL] [Abstract][Full Text] [Related]
20. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
Niessen F; Hilger T; Hoehn M; Hossmann KA
Stroke; 2003 Aug; 34(8):2019-24. PubMed ID: 12843350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
